UK biotech firm Edixomed has developed new wound care system, EDX110, which can heal diabetic foot ulcers dramatically faster and more effectively than current standard care

 “Diabetic foot ulcers are notoriously hard to heal, and are the leading cause of diabetes-related amputations in the UK. The findings reported today provide an essential step forward in developing solutions for the effective management of these chronic wounds,” said Professor Michael Edmonds, Principal Investigator, King’s College Hospital, London.

 “Reducing infection and accelerating healing could significantly contribute to a reduction in the number of avoidable amputations. EDX110 represents a major step forward in best practice care.”

EDX110 provides a protective and cushioning layer that uniquely absorbs fluid while providing a moist environment and generating nitric oxide.

The findings of this study support the unique potential of EDX110’s core technology: a sustained-release nitric oxide generating platform, that can be delivered as a dressing, liquid, gel or inhaled spray, with potential application in a variety of serious, underserved conditions and public health challenges, such as antimicrobial resistance (AMR)

Results from the pivotal clinical study, conducted in major UK treatment centres and involving 148 diabetic foot ulcers, showed that in 12 weeks, EDX110 reduced ulcer size by almost double the amount standard-of-care achieved (89% vs. 47%).

EDX110 also increased the number of completely healed ulcers by more than 50% (49% vs. 30%), nearly doubled the complete healing of infected ulcers (45% vs. 23%) and significantly reduced hospitalisations and serious adverse events related to the ulcer, compared with standard-of-care at 12 weeks.1

Through its novel mode-of-action, Edixomed’s unique technology safely harnesses a key molecule in the body’s own defences, nitric oxide, to amplify the body’s own response in fighting infection, improving healing and potentially increasing the activity of any prescribed antibiotic. Laboratory tests have shown EDX110 rapidly and safely kills bacteria, viruses and fungi, including several deadly antibiotic-resistant infections, such as MRSA and E. Coli.[ii],[iii]

“Infections resistant to all currently available antibiotics are expected to kill 10 million people a year by 2050. The threat is very real but with this technology, we have a viable and innovative solution to strike back with, and wound care is just the first of many potential applications of this new technology” said Professor Art Tucker, St Bartholomew's Hospital, London.

Edixomed chief medical officer professor Chris Wood said: “We are excited by the results we have seen in the clinic and lab, and are working to maximise the potential benefit to as many patients as possible, as quickly as possible. Edixomed has developed a completely new, important solution to the problem of chronic wound care and the major issue of antimicrobial resistance.

“This is a powerful and versatile core technology with many potential applications,  and we are actively pursuing a global strategy in partnership with leading innovation, clinical and distribution networks, to maximise the impact of this potentially disruptive technology.”

EDX110 is a revolutionary, easy-to-use, 2-part wound care system, driven by Edixomed’s core sustained-release nitric oxide delivery technology.

EDX110 provides a protective and cushioning layer that uniquely absorbs fluid while providing a moist environment and generating nitric oxide.

The role of nitric oxide in ulcer healing involves three recognised elements: vascular, as nitric oxide influences the widening of blood vessels (vasodilatation) and stimulates the growth of new blood vessels (angiogenesis);[iv],[v] inflammatory, as nitric oxide influences the body’s immune response;[vi] and antimicrobial, as nitric oxide demonstrates potent, broad spectrum antimicrobial activity.

Source: Company Press Release